Seres Therapeutics Inc. (MCRB) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Seres Therapeutics Inc.

    NASDAQ: MCRB · Real-Time Price · USD
    20.59
    -0.45 (-2.14%)
    At close: Oct 03, 2025, 3:59 PM
    20.59
    0.00%
    After-hours: Oct 03, 2025, 06:36 PM EDT

    Seres Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 126.33M 7.13M 144.93M
    Cost of Revenue
    		 14.7M 704K 1M 141.89M
    Gross Profit
    		 -14.7M 125.62M 6.12M 144.93M
    Operating Income
    		 -121.31M -107.98M -246.49M -64.49M
    Interest Income
    		 3.97M 7.3M 3.06M 2.87M
    Pretax Income
    		 -125.77M -113.72M -250.16M -65.58M
    Net Income
    		 136K -113.72M -250.16M -65.58M
    Selling & General & Admin
    		 53.18M 87.74M 79.69M 69.26M
    Research & Development
    		 64.6M 145.86M 172.92M 141.89M
    Other Expenses
    		 -14.43M n/a 1M -1.73M
    Operating Expenses
    		 103.35M 233.6M 253.62M 209.42M
    Interest Expense
    		 n/a 13.18M 6.02M 2.91M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 121.31M 234.31M 253.62M 209.42M
    Income Tax Expense
    		 n/a n/a 3.67M -4.08M
    Shares Outstanding (Basic)
    		 155.4M 128M 108.08M 4.59M
    Shares Outstanding (Diluted)
    		 7.77M 128M 108.08M 4.59M
    EPS (Basic)
    		 0.00 -0.89 -2.31 -14.3
    EPS (Diluted)
    		 -18.86 -0.89 -2.31 -14.3
    EBITDA
    		 -111.07M -94.31M -237.51M -56.72M
    EBIT
    		 -125.77M -100.55M -244.14M -62.67M
    Depreciation & Amortization
    		 14.7M 6.24M 6.63M 5.95M

    Add to Watchlist